Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Tumor regression grade and overall survival following gastrectomy with neoadjuvant therapy for gastric cancer.
Authors
Michelle A Savoldy
USF Morsani College of Medicine, Tampa, FL
Michelle A Savoldy , Andrew J Sinnamon , Rutika Mehta , Luis Pena , Sean P. Dineen , Gregory Y Lauwers , Jose Mario Pimiento
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
DOI
10.1200/JCO.2022.40.4_suppl.355
Abstract #
355
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tumor regression grade after neoadjuvant chemotherapy in patients with locally advanced gastric cancer treated with modern chemotherapy (FLOT): Experience in patients in Guatemala.
First Author: Rixci Ramirez
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Serum IL-6 level to predict survival and treatment response in gastric and gastroesophageal junction cancer.
First Author: John D Karalis
Poster
2019 Gastrointestinal Cancers Symposium
Tumor regression grade in gastric cancer after preoperative therapy.
First Author: Naruhiko Ikoma
Poster
2018 ASCO Annual Meeting
Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501).
First Author: Yoshiaki Iwasaki